anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)
AG-27B-6004PF-C100100 µgCHF 480.00
|Synonyms||ZIKV E Protein|
|Product Type||Recombinant Antibody|
Functional Application (Neutralizing): Neutralizes Zika Virus (ZIKV) with an IC50 of ~93ng/ml. Also enhances ZIKV infection in non-permissive K562 cells at a broad range of concentrations (not above 1µg/ml).
Optimal conditions should be determined individually.
|Specificity||Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E).|
|Purity Detail||Protein A-affinity purified.|
|Formulation||Liquid. In PBS.|
|Other Product Data||Source: EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naïve human donors.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
Stable for at least 1 year after receipt when stored at -20°C.
Stable for at least 3 months after receipt when stored at +4°C.
|Product Specification Sheet|
The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry; EDII containing the fusion loop; and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.
- Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection: K. Stettler, et al.; Science 353, 823 (2016)